Ekulizumab
(преусмерено са Eculizumab)
| Klinički podaci | |
|---|---|
| Prodajno ime | Soliris, Soliris (Alexion Pharmaceuticals) |
| Drugs.com | Monografija |
| Način primene | Intravenozno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 82 h |
| Identifikatori | |
| CAS broj | 219685-50-4  |
| ATC kod | None |
| DrugBank | DB01257 |
| ChEMBL | CHEMBL1201828 |
| Hemijski podaci | |
| Molarna masa | 148 kDa |
Ekulizumab (INN i USAN; prodajno ime Soliris) jeste humanizovano monoklonalno antitelo. Ono je prvo u klasi terminalnih inhibitora komplementa, kao i prva terapija koja je odobrena za lečenje paroksizmalne noćne hemoglobinurije (PNH), retke, progresivne, i u pojedinim slučajevima smrtonosne bolesti karakterisane prekomernim uništavanjem crvenih krvnih zrnaca (hemolizom).[1][2][3][4][5][6][7]
Reference[уреди | уреди извор]
- ^ Hillmen, Young, Schubert, P, N, J; et al. (2006). „The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria”. N Engl J Med. 355 (12): 1233—1243. PMID 16990386. doi:10.1056/NEJMMoa061648.
- ^ Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43. PMID 16990386
- ^ Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ: Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33(17-18):1389-401. PMID 9171898
- ^ Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R: FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008 Sep;13(9):993-1000. Epub 2008 Sep 10. PMID 18784156
- ^ Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 Nov;25(11):1256-64. PMID 17989688
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
